Dendreon Announces Data Presentations and Webcast at AUA Annual Meeting
24 April 2009 - 9:30PM
PR Newswire (US)
SEATTLE, April 24 /PRNewswire-FirstCall/ -- Dendreon Corporation
(NASDAQ: DNDN) today announced the following data presentations
taking place at the American Urological Association's (AUA) Annual
Meeting in Chicago, as well as a Dendreon-sponsored IMPACT data
webcast conference call: -- April 28, 2009, 2:20 p.m. CDT - "A
randomized, double-blind, placebo-controlled, multi-center, phase
III trial of sipuleucel-T in men with metastatic, androgen
independent prostatic adenocarcinoma (AIPC)." AUA Late-Breaking
Science Forum to be held from 1:00 p.m. to 2:30 p.m. CDT. Room W375
at McCormick Place -- April 28, 2009, 10:30 a.m. to 12:30 p.m. CDT
- Abstract #1408: "Preclinical Evaluation of the TRPM8 Ion Channel
Agonist D-3263 for Benign Prostatic Hyperplasia." Poster
presentation to occur in the Benign Prostatic Hyperplasia: Basic
Research session. Room W375B at McCormick Place -- April 28, 2009,
4:30 p.m. CDT - IMPACT data webcast conference call The IMPACT
(IMmunotherapy for Prostate AdenoCarcinoma Treatment) study
evaluated PROVENGE(R) (sipuleucel-T), Dendreon's investigational
product candidate for men with advanced prostate cancer
representing the first in a new class of active cellular
immunotherapies specifically designed to engage the patient's own
immune system against cancer. Dendreon announced last week that the
IMPACT trial met its primary endpoint of improving overall survival
compared to a placebo control. To access the live conference call,
dial 1-877-675-4753 (domestic) or 719-325-4864 (international). The
call also will be audio webcast and will be available from the
Company's website at http://www.dendreon.com/ under the
"Investor/Webcasts and Presentations" section. There will be a
slide presentation to accompany the call, which will also be
available on this section of the Dendreon website. A recorded
rebroadcast will be available for interested parties unable to
participate in the live conference call by dialing 1-888-203-1112
(domestic) or 719-457-0820 (international); the conference ID
number is 6483399. The replay will be available from 8:00 p.m. ET,
April 28, 2009 until midnight April 29, 2009. In addition, the
webcast will be archived for on-demand listening for 30 days at
http://www.dendreon.com/. About Dendreon Dendreon Corporation is a
biotechnology company whose mission is to target cancer and
transform lives through the discovery, development and
commercialization of novel therapeutics. The Company applies its
expertise in antigen identification, engineering and cell
processing to produce active cellular immunotherapy product
candidates designed to stimulate an immune response. Dendreon is
also developing an orally-available small molecule that targets
TRPM8 that could be applicable to multiple types of cancer as well
as benign prostatic hyperplasia. The Company has its headquarters
in Seattle, Washington and is traded on the Nasdaq Global Market
under the symbol DNDN. For more information about the Company and
its programs, visit http://www.dendreon.com/. DATASOURCE: Dendreon
Corporation CONTACT: Jennifer Cook Williams, Investor Relations of
Dendreon Corporation, +1-206-829-1500; or media, Katherine Stueland
of WeissComm Partners, +1-312-608-0320, , for Dendreon Corporation
Web Site: http://www.dendreon.com/
Copyright